A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PDE5i / PDE5 inhibitors

[Related PubMed/MEDLINE]
Total Number of Papers: 35
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PDE5i  (>> Co-occurring Abbreviation)
Long Form:   PDE5 inhibitors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. BPH, PCa
2019 Adherence and barriers to penile rehabilitation over 2 years following radical prostatectomy. ED, PR, VCD
2019 Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review. PDE, PDE3i, PDE4i, PDEs
2019 Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. ANP, PAH
2019 Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review. IELT, PE, PEP
2019 Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction. CBT, ED, PDE5
2019 The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective. CLTA, CVOD, ED, PD
2018 Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. A2AR, MCT, PAs, PH, RV
2016 Mesenchymal stem cell-based gene therapy for erectile dysfunction. ---
10  2016 PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. EAT, SIRT1, VAT
11  2016 Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. CAD, ED, PAH
12  2015 Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients? AR, ED
13  2015 Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men. ---
14  2015 Landmarks in erectile function recovery after radical prostatectomy. ED
15  2015 PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction. TES
16  2015 Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation. BM-SS, ICP, NOS, PDE5, PKG, ROS, SCD, WT
17  2014 Changes in sexual inhibition and excitation during PDE5I therapy. EF, MM
18  2014 Sildenafil attenuates inflammation and oxidative stress in pelvic ganglia neurons after bilateral cavernosal nerve damage. IL-1, iNOS, MPG, MPO, NADPH, TGF-beta1
19  2013 Daily dosing of PDE5 inhibitors: where does it fit in? BPH, ED, LUTS
20  2013 [Advances in the studies of refractory erectile dysfunction]. ED
21  2012 Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. LVEF, MDSC
22  2011 Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. ARO, PDE5, qRT-PCR
23  2011 Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. ED
24  2011 Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. ETB, HIF-1alpha, LUT, PDE5, SHR, WKY
25  2011 Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. ED, PDEs
26  2010 Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. ---
27  2009 A literature review and case reports series on the use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction. ---
28  2008 Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. ED, SELDI
29  2007 Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. PDEs
30  2007 Which patients with sexual dysfunction are suitable for testosterone replacement therapy? cGMP, ED, LOH, NOS, PDE5, SD, TDS
31  2006 Significance of hypogonadism in erectile dysfunction. ED
32  2005 Erectile dysfunction: molecular biology, pathophysiology and pharmacological treatment. cGMP, ED, PDE5
33  2005 PDE5 inhibitors and permanent visual loss. NAION
34  2005 Phosphodiesterase type 5 inhibitors for erectile dysfunction. ED
35  2004 [Cardiovascular safety of vardenafil]. ---